Literature DB >> 28599450

The distribution of human rectal aberrant crypt foci and criteria for defining the counting area.

Tetsuro Fujii1, Eiji Sakai1, Hirokazu Takahashi1, Eiji Yamada1, Hidenori Ohkubo1, Takuma Higurashi1, Atsushi Nakajima1.   

Abstract

Aberrant crypt foci (ACF) are considered as a useful surrogate biomarker for colorectal cancer, although their biological significance still remains controversial. We conducted this study to clarify whether differences in the ACF counting area might have led to the discrepancies in the ACF counts among previous reports. A endoscopist proficient in ACF counting performed high-magnification chromoscopic colonoscopy in 45 subjects and investigated the distribution of ACF in four bowel segments (middle Houston valve to the dentate line and distal rectum 0-5, 5-10 and 10-15 cm). We also investigated whether the patient physique might affect the distance from the middle Houston valve to the dentate line. The prevalence of ACF was 84% and most of the ACF (170/210, 81%) were located in the bowel segment from the middle Houston valve to the dentate line. The number of ACF was significantly correlated with the bowel segment in which the counting was performed: Dentate line to the middle Houston valve and distal rectum within 0-15 cm (r=0.94, P<0.001). The patient physique did not affect the distance from the middle Houston valve to the dentate line. In conclusion, the definition of the ACF counting area may not affect the results of ACF counting.

Entities:  

Keywords:  aberrant crypt foci; colorectal carciogenesis; high-magnification chromoscopic colonoscopy

Year:  2017        PMID: 28599450      PMCID: PMC5452945          DOI: 10.3892/ol.2017.6003

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  22 in total

1.  Investigation of the prevalence and number of aberrant crypt foci associated with human colorectal neoplasm.

Authors:  Eiji Sakai; Hirokazu Takahashi; Shingo Kato; Takashi Uchiyama; Kunihiro Hosono; Hiroki Endo; Shin Maeda; Masato Yoneda; Masataka Taguri; Atsushi Nakajima
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-07-12       Impact factor: 4.254

2.  Natural history of human aberrant crypt foci and correlation with risk factors for colorectal cancer.

Authors:  Hidenori Ohkubo; Hirokazu Takahashi; Eiji Yamada; Eiji Sakai; Takuma Higurashi; Takashi Uchiyama; Kunihiro Hosono; Hiroki Endo; Masataka Taguri; Atsushi Nakajima
Journal:  Oncol Rep       Date:  2012-01-12       Impact factor: 3.906

3.  Assessment of rectal aberrant crypt foci by standard chromoscopy and its predictive value for colonic advanced neoplasms.

Authors:  Kazuhiro Seike; Keiji Koda; Kenji Oda; Chihiro Kosugi; Kimio Shimizu; Masaki Nishimura; Masanobu Shioiri; Shigetsugu Takano; Hiroshi Ishikura; Masaru Miyazaki
Journal:  Am J Gastroenterol       Date:  2006-06       Impact factor: 10.864

4.  Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial.

Authors:  Kunihiro Hosono; Hiroki Endo; Hirokazu Takahashi; Michiko Sugiyama; Eiji Sakai; Takashi Uchiyama; Kaori Suzuki; Hiroshi Iida; Yasunari Sakamoto; Kyoko Yoneda; Tomoko Koide; Chikako Tokoro; Yasunobu Abe; Masahiko Inamori; Hitoshi Nakagama; Atsushi Nakajima
Journal:  Cancer Prev Res (Phila)       Date:  2010-09-01

5.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

6.  Randomized double-blind trial of sulindac and etodolac to eradicate aberrant crypt foci and to prevent sporadic colorectal polyps.

Authors:  Tetsuji Takayama; Hiroyuki Nagashima; Masahiro Maeda; Shuichi Nojiri; Michiaki Hirayama; Yoichiro Nakano; Yasuo Takahashi; Yasushi Sato; Hitoshi Sekikawa; Mitsuru Mori; Tomoko Sonoda; Tetsuo Kimura; Junji Kato; Yoshiro Niitsu
Journal:  Clin Cancer Res       Date:  2011-03-08       Impact factor: 12.531

7.  Aberrant crypt foci in the adenoma prevention with celecoxib trial.

Authors:  Nancy L Cho; Mark Redston; Ann G Zauber; Adelaide M Carothers; Jason Hornick; Andrew Wilton; Stephen Sontag; Norman Nishioka; Francis M Giardiello; John R Saltzman; Chris Gostout; Craig J Eagle; Ernest T Hawk; Monica M Bertagnolli
Journal:  Cancer Prev Res (Phila)       Date:  2008-04-14

8.  Endoscopic identification and quantification of aberrant crypt foci in the human colon.

Authors:  Douglas G Adler; Christopher J Gostout; Darius Sorbi; Lawrence J Burgart; Linan Wang; W Scott Harmsen
Journal:  Gastrointest Endosc       Date:  2002-11       Impact factor: 9.427

9.  Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup.

Authors:  S J Winawer; A G Zauber; M N Ho; M J O'Brien; L S Gottlieb; S S Sternberg; J D Waye; M Schapiro; J H Bond; J F Panish
Journal:  N Engl J Med       Date:  1993-12-30       Impact factor: 91.245

10.  Aberrant crypts: putative preneoplastic foci in human colonic mucosa.

Authors:  T P Pretlow; B J Barrow; W S Ashton; M A O'Riordan; T G Pretlow; J A Jurcisek; T A Stellato
Journal:  Cancer Res       Date:  1991-03-01       Impact factor: 12.701

View more
  1 in total

1.  Arsenic trioxide exposure accelerates colon preneoplasic aberrant crypt foci induction regionally through mitochondrial dysfunction.

Authors:  Hichem Moulahoum; Belkacem Mohamed Amine Boumaza; Meriem Ferrat; Bahia Djerdjouri
Journal:  Toxicol Res (Camb)       Date:  2017-09-27       Impact factor: 3.524

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.